专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005121130A3 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS 审中-公开
标题翻译：化学化合物和含有治疗炎症性疾病的药物组合物
公开(公告)号：WO2005121130A3
公开(公告)日：2006-07-20
申请号：PCT/US2005019131
申请日：2005-06-01
申请人： SCHERING CORP , GUO ZHUYAN , ORTH PETER , ZHU ZHAONING , MAZZOLA ROBERT D , CHAN TIN YAU , VACCARO HENRY A , MC KITTRICK BRIAN , KOZLOWSKI JOSEPH A , LAVEY BRIAN J , ZHOU GUOWEI , PALIWAL SUNIL , WONG SHING-CHUN , SHIH NENG-YANG , TING PAULINE C , ROSNER KRISTIN E , SHIPPS GERALD W JR , SIDDIQUI M ARSHAD , BELANGER DAVID B , DAI CHAOYANG , LI DANSU , GIRIJAVALLABHAN VINAY M , POPOVICI-MULLER JANETA , YU WENSHENG , ZHAO LIANYUN
发明人： GUO ZHUYAN , ORTH PETER , ZHU ZHAONING , MAZZOLA ROBERT D , CHAN TIN YAU , VACCARO HENRY A , MC KITTRICK BRIAN , KOZLOWSKI JOSEPH A , LAVEY BRIAN J , ZHOU GUOWEI , PALIWAL SUNIL , WONG SHING-CHUN , SHIH NENG-YANG , TING PAULINE C , ROSNER KRISTIN E , SHIPPS GERALD W JR , SIDDIQUI M ARSHAD , BELANGER DAVID B , DAI CHAOYANG , LI DANSU , GIRIJAVALLABHAN VINAY M , POPOVICI-MULLER JANETA , YU WENSHENG , ZHAO LIANYUN
IPC分类号： C07D409/12 , A61K31/40 , A61K31/4025 , A61K31/403 , A61K31/4427 , A61K31/47 , A61K31/495 , A61K31/496 , A61P19/02 , C07C233/18 , C07C235/06 , C07C235/08 , C07C235/10 , C07D207/20 , C07D207/26 , C07D209/44 , C07D215/14 , C07D217/06 , C07D263/32 , C07D295/18 , C07D295/185 , C07D307/52 , C07D333/20 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D498/04 , C07D513/04
CPC分类号： C07D409/14 , C07C235/06 , C07C235/08 , C07C235/10 , C07C2601/08 , C07D207/20 , C07D207/26 , C07D209/44 , C07D215/14 , C07D217/06 , C07D263/32 , C07D295/185 , C07D307/52 , C07D333/20 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D513/04
摘要： This invention relates to compounds of the Formula (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-a or combinations thereof.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物或异构体，其可用于治疗由MMP，ADAM，TACE，TNF-α或其组合介导的疾病或病症。

2. 发明申请

WO2007084415A2 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS 审中-公开
标题翻译：用于治疗炎症性疾病的化合物
公开(公告)号：WO2007084415A2
公开(公告)日：2007-07-26
申请号：PCT/US2007000930
申请日：2007-01-16
申请人： SCHERING CORP , YU WENSHENG , TONG LING , CHEN LEI , KOZLOWSKI JOSEPH A , LAVEY BRIAN J , SHIH NENG-YANG , MADISON VINCENT S , ZHOU GUOWEI , ORTH PETER , GUO ZHUYAN , WONG MICHAEL K C , YANG DE-YI , KIM SEONG-HEON , SHANKAR BANDARPALLE B , SIDDIQUI M ARSHAD , ROSNER KRISTIN E , DAI CHAOYANG , POPOVICI-MULLER JANETA , GIRIJAVALLABHAN VINAY M , LI DANSU , RIZVI RAZIA , MICULA ANETA S , FELTZ ROBERT
发明人： YU WENSHENG , TONG LING , CHEN LEI , KOZLOWSKI JOSEPH A , LAVEY BRIAN J , SHIH NENG-YANG , MADISON VINCENT S , ZHOU GUOWEI , ORTH PETER , GUO ZHUYAN , WONG MICHAEL K C , YANG DE-YI , KIM SEONG-HEON , SHANKAR BANDARPALLE B , SIDDIQUI M ARSHAD , ROSNER KRISTIN E , DAI CHAOYANG , POPOVICI-MULLER JANETA , GIRIJAVALLABHAN VINAY M , LI DANSU , RIZVI RAZIA , MICULA ANETA S , FELTZ ROBERT
CPC分类号： C07D403/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D473/34 , C07D487/04 , C07D491/04 , C07D495/04
摘要： This invention relates to compounds of the Formula (I) or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物，酯或异构体，其可用于治疗由MMP，ADAM，TACE，聚集蛋白聚糖酶，TNF-或其组合介导的疾病或病症。

3. 发明申请

WO2010056630A8 TRIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF 审中-公开
标题翻译：三唑并嘧啶酮及其使用方法
公开(公告)号：WO2010056630A8
公开(公告)日：2011-01-27
申请号：PCT/US2009063786
申请日：2009-11-10
申请人： SCHERING CORP , SHIPPS GERALD W JR , ORTH PETER , VOIGT JOHANNES H
发明人： SHIPPS GERALD W JR , ORTH PETER , VOIGT JOHANNES H
IPC分类号： A61K31/522 , A61P3/04 , A61P9/00
CPC分类号： A61K31/522
摘要： The present invention discloses a method of treating a cardiovascular disease or condition comprising administering therapeutically effective amounts of certain triazolopyrimidinones as Fatty Acid Binding Protein ("FABP") inhibitors. Examples of such disease or condition include metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative inventive method to treat the above-noted conditions uses the administration of the compound shown below: (I)
摘要翻译：本发明公开了一种治疗心血管疾病或病症的方法，包括给予治疗有效量的某些三唑并嘧啶酮作为脂肪酸结合蛋白（“FABP”）抑制剂。这种疾病或病症的实例包括代谢紊乱，肥胖或肥胖相关疾病，糖尿病，血脂异常，糖尿病并发症，葡萄糖耐量降低或空腹血糖受损。用于治疗上述病症的说明性发明方法使用下列化合物的施用：（I）

4. 发明申请

WO2014004436A3 CRYSTALLINE ANTI-HUMAN IL-23 ANTIBODIES 审中-公开
标题翻译：结晶抗人IL-23抗体
公开(公告)号：WO2014004436A3
公开(公告)日：2014-12-04
申请号：PCT/US2013047500
申请日：2013-06-25
申请人： MERCK SHARP & DOHME , REICHERT PAUL , PROSISE WINIFRED W , ORTH PETER , NARASIMHAN CHAKRAVARTHY NACHU , KASHI RAMESH S
发明人： REICHERT PAUL , PROSISE WINIFRED W , ORTH PETER , NARASIMHAN CHAKRAVARTHY NACHU , KASHI RAMESH S
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K39/39591 , C07K2299/00 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL- 23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.
摘要翻译：提供了对人IL-23的抗体的结晶形式，例如针对人IL-23p19的抗体，以及产生此类结晶形式的方法，以及使用这种结晶形式，例如，治疗炎症，自身免疫和增殖性疾病。在各种实施方案中，本发明的抗hulL-23p19抗体晶体可以通过分批结晶法，蒸气扩散法，液 - 液扩散法和透析法获得。在其它方面，本发明涉及本发明的结晶抗hulL-23抗体的悬浮液，包括在相同抗体浓度下与相应的非结晶溶液相比可能的浓度和粘度更低的那些。在其它实施方案中，本发明的抗-HLL-23抗体晶体具有提高的稳定性，即它们比抗相对应的溶液制剂更长时间保持抗-HuiL-23抗体（例如抗-HLL-23p19抗体）的生物学活性。

5. 发明申请

WO2005018635A3 ION CHANNEL MODULATING ACTIVITY I 审中-公开
标题翻译：离子通道调节活性
公开(公告)号：WO2005018635A3
公开(公告)日：2005-05-12
申请号：PCT/US2004025889
申请日：2004-08-09
申请人： CARDIOME PHARMA CORP , FEDIDA DAVID , BEATCH GREGORY N , EZRIN ALAN M , ORTH PETER , HESKETH CHRISTIAN
发明人： FEDIDA DAVID , BEATCH GREGORY N , EZRIN ALAN M , ORTH PETER , HESKETH CHRISTIAN
IPC分类号： A61K31/40 , A61K31/455 , A61K31/4965 , A61K31/519 , A61P9/06 , C07D207/12 , A61K31/18
CPC分类号： A61K31/40 , A61K31/455 , A61K31/4965 , A61K31/519 , C07D207/12
摘要： Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
摘要翻译：用于治疗或预防心律失常的方法，组合物，给药方案和给药途径。在这些方法中，可以通过向有需要的受试者施用离子通道调节化合物来减少或消除早期后消极和延长QT间期。离子通道调节化合物可以是环烷基胺醚化合物，特别是环己胺醚化合物。还描述了诱导早期后极化，延长QT间期和/或Torsades de Pointes的离子通道调节化合物和药物的组合物。

6. 发明申请

WO2004031427A3 METHOD FOR PRODUCING A MOULDED BODY FROM SINTERED STEEL 审中-公开
标题翻译：方法制备成型身体SINTERSTAHL
公开(公告)号：WO2004031427A3
公开(公告)日：2004-10-28
申请号：PCT/AT0300292
申请日：2003-09-30
申请人： MIBA SINTERMETALL GMBH , RATZI RAIMUND , ORTH PETER , BOUVIER ALEXANDER , REGENFELDER WALTER , HARTL STEFAN
发明人： RATZI RAIMUND , ORTH PETER , BOUVIER ALEXANDER , REGENFELDER WALTER , HARTL STEFAN
IPC分类号： B01J31/02 , B22F3/10 , C07B61/00 , C07D213/89 , C22C33/02
CPC分类号： C22C33/0207 , B22F3/1035 , B22F2999/00
摘要： The invention relates to a method for producing a moulded body from sintered steel. According to said method, a sintered powder based on iron is mixed with a master alloy powder containing nickel, boron and iron, and the powder mixture is compressed to form a blank which is then sintered under conditions of a liquid phase sintering with a part by volume in the liquid phase of up to 15 %. In order to improve the impact strength, the boron content of the powder mixture is between 0.03 and 0.2 wt. % when the boron part of the master alloy powder is less than 10 wt. %, the weight ratio between the nickel part and the boron part of the powder mixture exceeds 5, and the master alloy powder has an average particle size of between 10 and 90 µm.
摘要翻译：本发明涉及一种方法，用于从烧结钢，其特征在于，有镍，硼，和含有铁基合金粉末的烧结铁基粉末混合，并将粉末混合物液相烧结的条件下进行压制，以模制所述模制之前具有一定体积的液体级分中生产的成型体相烧结至15％。为了提高冲击强度，％提出了重量的粉末混合物的硼含量在0.03小于10重量的母合金的硼含量为0.2。％的所述镍和的硼含量之间的重量比粉末混合物超过5，并且该母合金粉末具有10个90微米之间的平均粒度。

7. 发明专利

DE1534351A1 未知
公开(公告)号：DE1534351A1
公开(公告)日：1969-07-03
申请号：DE1534351
申请日：1951-01-28
申请人： ORTH PETER
发明人： ORTH PETER
IPC分类号： E01C3/00 , E01C7/16 , E01C19/50

8. 发明专利

AT263508B 未知
公开(公告)号：AT263508B
公开(公告)日：1968-07-25
申请号：AT594766
申请日：1966-06-22
申请人： ORTH PETER
发明人： ORTH PETER
IPC分类号： B21D53/04

9. 发明专利

DE1894557U 未知
公开(公告)号：DE1894557U
公开(公告)日：1964-06-11
申请号：DEO0007298
申请日：1963-10-30
申请人： ORTH PETER
发明人： ORTH PETER

10. 发明专利

ATA901374A 未知
公开(公告)号：ATA901374A
公开(公告)日：1978-01-15
申请号：AT901374
申请日：1974-11-11
申请人： ORTH PETER
发明人： ORTH PETER
IPC分类号： B21D13/04 , B21D17/04

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式